Regenerative Medical Technology (RMTG) Cash from Investing Activities (2020 - 2026)
Regenerative Medical Technology (RMTG) posted quarterly Cash from Investing Activities of -$315394.0 for Q1 2026, down 18.05% quarter-over-quarter from -$267172.0 in Q4 2025.
Regenerative Medical Technology (RMTG) Cash from Investing Activities (2020 - 2026) Analysis & Trends
Regenerative Medical Technology's Cash from Investing Activities history runs 7 years deep, the most recent figure standing at -$315394.0 for Q1 2026.
- In Q1 2026, Cash from Investing Activities changed N/A year-over-year to -$315394.0; the TTM figure through Mar 2026 stood at -$857395.0 (changed N/A YoY), while the FY2025 annual figure was -$602583.0, down 179.73% from the prior year.
- Cash from Investing Activities for Q1 2026 stood at -$315394.0, down from -$267172.0 in the prior quarter.
- The five-year high for Cash from Investing Activities was -$1262.0 in Q3 2022, with the low at -$315394.0 in Q1 2026.
- The 5-year median for Cash from Investing Activities is -$59154.0 (2024), against an average of -$113707.6.
- The sharpest annual moves came in 2022 and 2024: Cash from Investing Activities slumped 37970.56% in 2022, then soared 82.39% in 2024.
- Regenerative Medical Technology's Cash from Investing Activities stood at -$68527.0 in 2022, then slumped by 314.44% to -$284002.0 in 2023, then jumped by 82.39% to -$50000.0 in 2024, then sank by 434.34% to -$267172.0 in 2025, then slipped by 18.05% to -$315394.0 in 2026.
- Business Quant data shows RMTG's Cash from Investing Activities at -$315394.0 in Q1 2026, -$267172.0 in Q4 2025, and -$224829.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -45.80 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -92.70 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 329.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | -49.35 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -363.46 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -3.17 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 24.51 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -229.72 Mn |
| 10 | Regenerative Medical Technology | 1.58 Mn | 515,228.12 | 1.77 Mn | -315,394.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -315,394.00 |
| Mar 31, 2026 | -315,394.00 |
| Dec 31, 2025 | -267,172.00 |
| Dec 31, 2025 | -267,172.00 |
| Sep 30, 2025 | -224,829.00 |
| Sep 30, 2025 | -224,829.00 |
| Dec 31, 2024 | -50,000.00 |
| Dec 31, 2024 | -50,000.00 |
| Sep 30, 2024 | -53,608.00 |
| Sep 30, 2024 | -53,608.00 |
| Jun 30, 2024 | -52,657.00 |
| Jun 30, 2024 | -52,657.00 |
| Mar 31, 2024 | -59,154.00 |
| Mar 31, 2024 | -59,154.00 |
| Dec 31, 2023 | -284,002.00 |
| Dec 31, 2023 | -284,002.00 |
| Sep 30, 2023 | -91,387.00 |
| Sep 30, 2023 | -91,387.00 |
| Jun 30, 2023 | -4,721.00 |
| Jun 30, 2023 | -4,721.00 |